Cargando…

Therapeutic approach to respiratory infections in lung transplantation

Lung transplant recipients (LTRs) are at life-long risk for infections and disseminated diseases owing to their immunocompromised state. Besides organ failure and sepsis, infection can trigger acute and chronic graft rejection which increases mortality. Medical prophylaxis and treatment are based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Clajus, Carolina, Blasi, Francesco, Welte, Tobias, Greer, Mark, Fuehner, Thomas, Mantero, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110868/
https://www.ncbi.nlm.nih.gov/pubmed/25038552
http://dx.doi.org/10.1016/j.pupt.2014.07.003
_version_ 1783513155778904064
author Clajus, Carolina
Blasi, Francesco
Welte, Tobias
Greer, Mark
Fuehner, Thomas
Mantero, Marco
author_facet Clajus, Carolina
Blasi, Francesco
Welte, Tobias
Greer, Mark
Fuehner, Thomas
Mantero, Marco
author_sort Clajus, Carolina
collection PubMed
description Lung transplant recipients (LTRs) are at life-long risk for infections and disseminated diseases owing to their immunocompromised state. Besides organ failure and sepsis, infection can trigger acute and chronic graft rejection which increases mortality. Medical prophylaxis and treatment are based on comprehensive diagnostic work-up including previous history of infection and airway colonisation to reduce long-term complications and mortality. Common bacterial pathogens include Pseudomonas and Staphylococcus, whilst Aspergillus and Cytomegalovirus (CMV) are respectively the commonest fungal and viral pathogens. Clinical symptoms can be various in lung transplant recipients presenting an asymptomatic to severe progress. Regular control of infection parameters, daily lung function testing and lifelong follow-up in a specialist transplant centre are mandatory for early detection of bacterial, viral and fungal infections. After transplantation each patient receives intensive training with rules of conduct concerning preventive behaviour and to recognize early signs of post transplant complications. Early detection of infection and complications are important goals to reduce major complications after lung transplantation.
format Online
Article
Text
id pubmed-7110868
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71108682020-04-02 Therapeutic approach to respiratory infections in lung transplantation Clajus, Carolina Blasi, Francesco Welte, Tobias Greer, Mark Fuehner, Thomas Mantero, Marco Pulm Pharmacol Ther Article Lung transplant recipients (LTRs) are at life-long risk for infections and disseminated diseases owing to their immunocompromised state. Besides organ failure and sepsis, infection can trigger acute and chronic graft rejection which increases mortality. Medical prophylaxis and treatment are based on comprehensive diagnostic work-up including previous history of infection and airway colonisation to reduce long-term complications and mortality. Common bacterial pathogens include Pseudomonas and Staphylococcus, whilst Aspergillus and Cytomegalovirus (CMV) are respectively the commonest fungal and viral pathogens. Clinical symptoms can be various in lung transplant recipients presenting an asymptomatic to severe progress. Regular control of infection parameters, daily lung function testing and lifelong follow-up in a specialist transplant centre are mandatory for early detection of bacterial, viral and fungal infections. After transplantation each patient receives intensive training with rules of conduct concerning preventive behaviour and to recognize early signs of post transplant complications. Early detection of infection and complications are important goals to reduce major complications after lung transplantation. Elsevier Ltd. 2015-06 2014-07-17 /pmc/articles/PMC7110868/ /pubmed/25038552 http://dx.doi.org/10.1016/j.pupt.2014.07.003 Text en Copyright © 2014 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Clajus, Carolina
Blasi, Francesco
Welte, Tobias
Greer, Mark
Fuehner, Thomas
Mantero, Marco
Therapeutic approach to respiratory infections in lung transplantation
title Therapeutic approach to respiratory infections in lung transplantation
title_full Therapeutic approach to respiratory infections in lung transplantation
title_fullStr Therapeutic approach to respiratory infections in lung transplantation
title_full_unstemmed Therapeutic approach to respiratory infections in lung transplantation
title_short Therapeutic approach to respiratory infections in lung transplantation
title_sort therapeutic approach to respiratory infections in lung transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110868/
https://www.ncbi.nlm.nih.gov/pubmed/25038552
http://dx.doi.org/10.1016/j.pupt.2014.07.003
work_keys_str_mv AT clajuscarolina therapeuticapproachtorespiratoryinfectionsinlungtransplantation
AT blasifrancesco therapeuticapproachtorespiratoryinfectionsinlungtransplantation
AT weltetobias therapeuticapproachtorespiratoryinfectionsinlungtransplantation
AT greermark therapeuticapproachtorespiratoryinfectionsinlungtransplantation
AT fuehnerthomas therapeuticapproachtorespiratoryinfectionsinlungtransplantation
AT manteromarco therapeuticapproachtorespiratoryinfectionsinlungtransplantation